Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents.

Literature DB >> 23857129

Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents.

Gabriel Herrero-Beaumont, Jorge A Roman-Blas.

Abstract

Beneficial effects of bone-acting drugs in osteoarthritis (OA) are increasingly reported, but reliable conclusions regarding their efficacy are hindered by methodological drawbacks in study design. Identifying patients with osteoporotic OA, a phenotype defined by decreased density associated with high remodelling in subchondral bone, might improve the success of bone-directed agents.

Entities: Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23857129 DOI： 10.1038/nrrheum.2013.113

Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543

9 in total

1. Clinical relevance of bone marrow lesions in OA.

Authors: C Kent Kwoh
Journal: Nat Rev Rheumatol Date: 2012-12-11 Impact factor: 20.543

2. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.

Authors: J C Buckland-Wright; E A Messent; C O Bingham; R J Ward; C Tonkin
Journal: Rheumatology (Oxford) Date: 2006-07-11 Impact factor: 7.580

3. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis.

Authors: M Bellido; L Lugo; J A Roman-Blas; S Castañeda; E Calvo; R Largo; G Herrero-Beaumont
Journal: Osteoarthritis Cartilage Date: 2011-07-23 Impact factor: 6.576

4. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative.

Authors: Laura L Laslett; Sarah R Kingsbury; Elizabeth M A Hensor; Michael A Bowes; Philip G Conaghan
Journal: Ann Rheum Dis Date: 2013-04-12 Impact factor: 19.103

5. Bone and cartilage in osteoarthritis: is what's best for one good or bad for the other?

Authors: Steven R Goldring; Mary B Goldring
Journal: Arthritis Res Ther Date: 2010-10-19 Impact factor: 5.156

6. Subchondral bone marrow lesions are highly associated with, and predict subchondral bone attrition longitudinally: the MOST study.

Authors: F W Roemer; T Neogi; M C Nevitt; D T Felson; Y Zhu; Y Zhang; J A Lynch; M K Javaid; M D Crema; J Torner; C E Lewis; A Guermazi
Journal: Osteoarthritis Cartilage Date: 2009-09-10 Impact factor: 6.576

Review 7. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics.

Authors: Gabriel Herrero-Beaumont; Jorge A Roman-Blas; Santos Castañeda; Sergio A Jimenez
Journal: Semin Arthritis Rheum Date: 2009-07-09 Impact factor: 5.532

8. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis.

Authors: Miriam Bellido; Laura Lugo; Jorge A Roman-Blas; Santos Castañeda; Jose R Caeiro; Sonia Dapia; Emilio Calvo; Raquel Largo; Gabriel Herrero-Beaumont
Journal: Arthritis Res Ther Date: 2010-08-02 Impact factor: 5.156

9. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.

Authors: Jean-Yves Reginster; Janusz Badurski; Nicholas Bellamy; William Bensen; Roland Chapurlat; Xavier Chevalier; Claus Christiansen; Harry Genant; Federico Navarro; Evgeny Nasonov; Philip N Sambrook; Timothy D Spector; Cyrus Cooper
Journal: Ann Rheum Dis Date: 2012-11-01 Impact factor: 19.103

9 in total

16 in total

1. Knee loading repairs osteoporotic osteoarthritis by relieving abnormal remodeling of subchondral bone via Wnt/β-catenin signaling.

Authors: Weiwei Zheng; Beibei Ding; Xinle Li; Daquan Liu; Hiroki Yokota; Ping Zhang
Journal: FASEB J Date: 2020-01-10 Impact factor: 5.191

Review 2. TLR4 signalling in osteoarthritis--finding targets for candidate DMOADs.

Authors: Rodolfo Gómez; Amanda Villalvilla; Raquel Largo; Oreste Gualillo; Gabriel Herrero-Beaumont
Journal: Nat Rev Rheumatol Date: 2014-12-16 Impact factor: 20.543

3. Targeting subchondral bone in osteoporotic osteoarthritis.

Authors: Jorge A Roman-Blas; Gabriel Herrero-Beaumont
Journal: Arthritis Res Ther Date: 2014-11-25 Impact factor: 5.156

4. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis.

Authors: Olivier Bruyère; Cyrus Cooper; Nigel Arden; Jaime Branco; Maria Luisa Brandi; Gabriel Herrero-Beaumont; Francis Berenbaum; Elaine Dennison; Jean-Pierre Devogelaer; Marc Hochberg; John Kanis; Andrea Laslop; Tim McAlindon; Susanne Reiter; Pascal Richette; René Rizzoli; Jean-Yves Reginster
Journal: Drugs Aging Date: 2015-03 Impact factor: 3.923

5. The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction.

Authors: Amanda Villalvilla; Adela García-Martín; Raquel Largo; Oreste Gualillo; Gabriel Herrero-Beaumont; Rodolfo Gómez
Journal: Sci Rep Date: 2016-07-07 Impact factor: 4.379

Review 6. Are estrogen-related drugs new alternatives for the management of osteoarthritis?

Authors: Ya-Ping Xiao; Fa-Ming Tian; Mu-Wei Dai; Wen-Ya Wang; Li-Tao Shao; Liu Zhang
Journal: Arthritis Res Ther Date: 2016-06-28 Impact factor: 5.156

7. The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis.

Authors: Erik Lindström; Biljana Rizoska; Karin Tunblad; Charlotte Edenius; Alison M Bendele; Don Maul; Michael Larson; Neha Shah; Valerie Yoder Otto; Chris Jerome; Urszula Grabowska
Journal: J Transl Med Date: 2018-03-09 Impact factor: 5.531